The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
Abstract
PURPOSE: To determine the efficacy (objective response rate and duration of response and survival) and toxicity of docetaxel in patients with strictly defined anthracycline-resistant metastatic breast cancer (MBC). PATIENTS AND METHODS: Thirty-five patients with bidimensionally measurable MBC who had progressive disease while receiving anthracycline-containing chemotherapy were registered onto the phase II trial. Docetaxel was administered at a dose of 100 mg/m2 over 1 hour every 21 days. RESULTS: Thirty-four patients were assessable for disease response; 18 (53%; 95% confidence interval [CI], 35% to 70%) achieved a partial response. The median times to disease progression and survival duration were 7.5 and 13.5 months, respectively, for responding patients. The median overall survival duration was 9 months. Two hundred eight cycles (median, five) of docetaxel were administered. Neutropenia with less than 500 cells/microL developed in 31 of 35 patients; it was complicated by fever in 30 (14%) of 208 cycles and in 18 (51%) of 35 patients, including one treatment-related death. Fluid retention was seen in 15 (43%) of 35 patients, including pleural effusions in 11 patients (31%). Moderate skin toxicity, asthenia, and myalgia were observed in 16%, 58%, and 37% of cycles, respectively. CONCLUSION: Docetaxel has the highest reported antitumor activity in anthracycline-resistant MBC. High objective response rates were seen in patients with visceral-dominant involvement, multiple metastatic sites, or extensive previous therapy. Docetaxel is associated with severe but reversible neutropenia, asthenia, and cumulative dose-related fluid retention. Dexamethasone decreased the frequency and severity of skin toxicity and appeared to ameliorate fluid retention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zubrod, C. G., Schneiderman, M., Frei, E., Brindley, C., Lennard Gold, G., Shnider, B., Oviedo, R., Gorman, J., Jones, R., Jonsson, U., et al. (1960) · Journal of Chronic Diseases · doi:10.1016/0021-9681(60)90137-5 · Cited by 1,034
One-Sample Multiple Testing Procedure for Phase II Clinical Trials
Fleming, T. R. (1982) · Biometrics · doi:10.2307/2530297 · Cited by 1,003
Assessment of response to therapy in advanced breast cancer
Hayward, J. L., Carbone, P. P., Heusen, J. C., Kumaoka, S., Segaloff, A., & Rubens, R. D. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.42 · Cited by 705
Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.
Bissery, M.-C., Guénard, D., Guéritte, F., & Lavelle, F. (1991) · PubMed · Cited by 481
Paclitaxel (TaxolTM) and docetaxel (TaxotereTM): Not simply two of a kind
Verweij, J., Clavel, M., & Chevalier, B. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058903 · Cited by 361
The taxoids: paclitaxel (Taxol®) and docetaxel (Taxotere®)
Pazdur, R., Kudelka, A. P., Kavanagh, J. J., Cohen, P. R., & Raber, M. N. (1993) · Cancer Treatment Reviews · doi:10.1016/0305-7372(93)90010-o · Cited by 278
Chevallier, B., Fumoleau, P., Kerbrat, P., Dieras, V. C., Roche, H. H., Krakowski, I., Azli, N., Bayssas, M., Lentz, M. A., & Glabbeke, M. M. V. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.2.314 · Cited by 221
Wilson, W. H., Berg, S. L., Bryant, G., Wittes, R. E., Bates, S., Fojo, A., Steinberg, S. M., Goldspiel, B. R., Herdt, J., & O'Shaughnessy, J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.8.1621 · Cited by 216
A’Hern, R., Smith, I., & Ebbs, S. R. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.146 · Cited by 197
Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer
Degardin, M., Bonneterre, J. M., Hecquet, B., Pion, J. M., Adeins, A., Horner, D., & Demaille, A. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058873 · Cited by 142
Cited by
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
“controls (Holmes et al., 1991; Valero et al., 1995).”
MethodBruno, R., Hille, D., Riva, A., Vivier, N., ten Bokkel Huinnink, W. W., van Oosterom, A. T., Kaye, S. B., Verweij, J., Fossella, F. V., Valero, V, et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.187 · Cited by 423
Self-citationLucien, F., Pelletier, P.-P., Lavoie, R. R., Lacroix, J.-M., Roy, S., Parent, J.-L., Arsenault, D., Harper, K., & Dubois, C. M. (2017) · Nature Communications · doi:10.1038/ncomms15884 · Cited by 66
Metadata
- Authors
- Valero, V, Holmes, F. A., Walters, R. S., Theriault, R. L., Esparza, L., Fraschini, G., Fonseca, G. A., Bellet, R. E., Buzdar, A. U., & Hortobagyi, G. N.
- Venue
- Journal of Clinical Oncology
- Published
- 1995-12
- Volume
- 13
- Issue
- 12
- Pages
- 2886-2894
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1955744924
- Cited by
- 386
- References
- 10
- FWCI
- 8.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. https://app.cochat.ai/papers/10.1200/jco.1995.13.12.2886
- The paper
- Valero, V, Holmes, F. A., Walters, R. S., Theriault, R. L., Esparza, L., Fraschini, G., Fonseca, G. A., Bellet, R. E., Buzdar, A. U., & Hortobagyi, G. N. (1995). Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1995.13.12.2886
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
